2. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353(23):2477–90. 10.1056/NEJMra043172

3. Lobo J, Ohashi R, Amin MB, Berney DM, Compérat EM, Cree IA, et al. WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology. 2022;81(4):426–38. 10.1111/his.14700

4. Linehan WM, Schmidt LS, Crooks DR, Wei D, Srinivasan R, Lang M, et al. The metabolic basis of kidney cancer. Cancer Discov. 2019;9(8):1006–21. 10.1158/2159-8290.CD-18-1354

5. Pfaffenroth EC, Linehan WM. Genetic basis for kidney cancer: Opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther. 2008;8(6):779–90. 10.1517/14712598.8.6.779

6. Patel HV, Srivastava A, Srinivasan R, Singer EA. A challenging frontier—The genomics and therapeutics of nonclear cell renal cell carcinoma. Curr Opin Oncol. 2021;33(3):212–20. 10.1097/CCO.0000000000000721

7. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20(23):4559–66. 10.1200/JCO.2002.05.111

8. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34. 10.1056/NEJMoa060655

9. Nelson EC, Evans CP, Lara PN, Jr. Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev. 2007;33(3):299–313. 10.1016/j.ctrv.2006.12.005

10. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am. 1993;20(2):303–21. 10.1016/S0094-0143(21)00489-4

11. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. 10.1056/NEJMoa1510665

12. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90. 10.1056/NEJMoa1712126

13. Palma Dos Reis AF, Simão D, Odeny T, Rodrigues C, Fontes-Sousa M, da Luz R, et al. A systematic review of immune checkpoint inhibitors in non-clear-cell renal cancer. Kidney Cancer. 2022;6(2):115–27. 10.3233/KCA-210012

14. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24. 10.1056/NEJMoa065044

15. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81. 10.1056/NEJMoa066838

16. Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, et al. Kidney cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2022;20(1):71–90. 10.6004/jnccn.2022.0001

17. Lee JL, Ahn JH, Lim HY, Park SH, Lee SH, Kim TM, et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol. 2012;23(8):2108–14. 10.1093/annonc/mdr586

18. Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPEN): A randomized multicenter phase 2 trial. Eur Urol. 2016;69(5):866–74. 10.1016/j.eururo.2015.10.049

19. Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): A multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17(3):378–88. 10.1016/S1470-2045(15)00515-X

20. Bergmann L, Grunwald V, Maute L, Grimm MO, Weikert S, Schleicher J, et al. A randomized phase IIa trial with temsirolimus versus sunitinib in advanced non-clear cell renal cell carcinoma: An intergroup study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society. Oncol Res Treat. 2020;43(7–8):333–9. 10.1159/000508450

21. Bukowski RM. Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma. Front Oncol. 2012;2:13. 10.3389/fonc.2012.00013

22. Jung KS, Lee SJ, Park SH, Lee JL, Lee SH, Lim JY, et al. Pazopanib for the treatment of non-clear cell renal cell carcinoma: A single-arm, open-label, multicenter, phase II study. Cancer Res Treat. 2018;50(2):488–94. 10.4143/crt.2016.584

23. Park I, Lee SH, Lee JL. A multicenter phase II trial of axitinib in patients with recurrent or metastatic non-clear-cell renal cell carcinoma who had failed prior treatment with temsirolimus. Clin Genitourin Cancer. 2018;16(5):e997–1002. 10.1016/j.clgc.2018.05.011

24. Voss MH, Molina AM, Chen YB, Woo KM, Chaim JL, Coskey DT, et al. Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma. J Clin Oncol. 2016;34(32):3846–53. 10.1200/JCO.2016.67.9084

25. Feldman DR, Ged Y, Lee CH, Knezevic A, Molina AM, Chen YB, et al. Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. Cancer. 2020;126(24):5247–55. 10.1002/cncr.33148

26. Vogelzang NJ, Olsen MR, McFarlane JJ, Arrowsmith E, Bauer TM, Jain RK, et al. Safety and efficacy of nivolumab in patients with advanced non-clear cell renal cell carcinoma: Results from the phase IIIb/IV checkMate 374 study. Clin Genitourin Cancer. 2020;18(6):461–8 e3. 10.1016/j.clgc.2020.05.006

27. McGregor BA, McKay RR, Braun DA, Werner L, Gray K, Flaifel A, et al. Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features. J Clin Oncol. 2020;38(1):63–70. 10.1200/JCO.19.01882

28. Apolo AB, Nadal R, Tomita Y, Davarpanah NN, Cordes LM, Steinberg SM, et al. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: An open-label, single-centre, phase 2 trial. Lancet Oncol. 2020;21(8):1099–1109. 10.1016/S1470-2045(20)30202-3

29. Pal SK, McGregor B, Suarez C, Tsao CK, Kelly W, Vaishampayan U, et al. Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: Results from the COSMIC-021 Study. J Clin Oncol. 2021;39(33):3725–36. 10.1200/JCO.21.00939

30. Lee CH, Voss MH, Carlo MI, Chen YB, Zucker M, Knezevic A, et al. Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates. J Clin Oncol. 2022:JCO2101944. 10.1200/JCO.21.01944

31. Massari F, Rizzo A, Mollica V, Rosellini M, Marchetti A, Ardizzoni A, et al. Immune-based combinations for the treatment of metastatic renal cell carcinoma: A meta-analysis of randomised clinical trials. Eur J Cancer. 2021;154:120–7. 10.1016/j.ejca.2021.06.015

32. Tykodi SS, Gordan LN, Alter RS, Arrowsmith E, Harrison MR, Percent I, et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: Results from the phase 3b/4 CheckMate 920 trial. J Immunother Cancer. 2022;10(2). 10.1136/jitc-2021-003844

33. Albiges L, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): A single-arm, multicentre, phase 2 trial. Lancet Oncol. 2023;24(8);881–91. 10.1016/S1470-2045(23)00276-0

34. Saleeb RM, Brimo F, Farag M, Rompré-Brodeur A, Rotondo F, Beharry V, et al. Toward biological subtyping of papillary renal cell carcinoma with clinical implications through histologic, immunohistochemical, and molecular analysis. Am J Surg Pathol. 2017;41(12):1618–29. 10.1097/PAS.0000000000000962

35. Chevarie-Davis M, Riazalhosseini Y, Arseneault M, Aprikian A, Kassouf W, Tanguay S, et al. The morphologic and immunohistochemical spectrum of papillary renal cell carcinoma: Study including 132 cases with pure type 1 and type 2 morphology as well as tumors with overlapping features. Am J Surg Pathol. 2014;38(7):887–94. 10.1097/PAS.0000000000000247

36. Moch H, Amin MB, Berney DM, Compérat EM, Gill AJ, Hartmann A, et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, penile, and testicular tumours. Eur Urol. 2022;82(5):458–68. 10.1016/j.eururo.2022.06.016

37. Carlo MI, Hakimi AA, Stewart GD, Bratslavsky G, Brugarolas J, Chen YB, et al. Familial kidney cancer: Implications of new syndromes and molecular insights. Eur Urol. 2019;76(6):754–64. 10.1016/j.eururo.2019.06.015

38. Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374(2):135–45. 10.1056/NEJMoa1505917

39. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16(1):68–73. 10.1038/ng0597-68

40. Pollard P, Wortham N, Barclay E, Alam A, Elia G, Manek S, et al. Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. J Pathol. 2005;205(1):41–9. 10.1002/path.1686

41. Srinivasan R, Gurram S, Harthy MA, Singer EA, Sidana A, Shuch BM, et al. Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. J Clin Oncol. 2020;38(15_suppl):5004. 10.1200/JCO.2020.38.15_suppl.5004

42. National Cancer I, National Institutes of Health Clinical C. A phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer [Internet]. [cited December 1, 2022]. Available from: https://ClinicalTrials.gov/show/NCT01130519

43. National Cancer I. Testing of bevacizumab, erlotinib, and atezolizumab for advanced-stage kidney cancer [Internet]. [cited July 10, 2023]. Available from: https://ClinicalTrials.gov/show/NCT04981509

44. Gordon MS, Hussey M, Nagle RB, Lara PN, Jr., Mack PC, Dutcher J, et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol. 2009;27(34):5788–93. 10.1200/JCO.2008.18.8821

45. Twardowski PW, Tangen CM, Wu X, Plets MR, Plimack ER, Agarwal N, et al. Parallel (randomized) phase II evaluation of tivantinib (ARQ197) and tivantinib in combination with erlotinib in papillary renal cell carcinoma: SWOG S1107. Kidney Cancer. 2017;1(2):123–32. 10.3233/KCA-170018

46. Ravaud A, Oudard S, De Fromont M, Chevreau C, Gravis G, Zanetta S, et al. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: A phase II study (SUPAP) by the French Genitourinary Group (GETUG) dagger. Ann Oncol. 2015;26(6):1123–8. 10.1093/annonc/mdv149

47. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31(2):181–6. 10.1200/JCO.2012.43.3383

48. Choueiri TK, Heng DYC, Lee JL, Cancel M, Verheijen RB, Mellemgaard A, et al. Efficacy of savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: The SAVOIR phase 3 randomized clinical trial. JAMA Oncol. 2020;6(8):1247–55. 10.1001/jamaoncol.2020.2218

49. Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DYC, Powles T, et al. Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer. J Clin Oncol. 2017;35(26):2993–3001. 10.1200/JCO.2017.72.2967

50. Schoffski P, Wozniak A, Escudier B, Rutkowski P, Anthoney A, Bauer S, et al. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. Eur J Cancer. 2017;87:147–63. 10.1016/j.ejca.2017.10.014

51. Pal SK, Tangen C, Thompson IM, Jr., Balzer-Haas N, George DJ, Heng DYC, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: A randomised, open-label, phase 2 trial. Lancet. 2021;397(10275):695–703. 10.1016/S0140-6736(21)00152-5

52. National Cancer I, National Institutes of Health Clinical C. A phase 2 study of the MET kinase inhibitor INC280 in papillary renal cell cancer [Internet]. [cited December 17, 2021]. Available from: https://ClinicalTrials.gov/show/NCT02019693.

53. Escudier B, Molinie V, Bracarda S, Maroto P, Szczylik C, Nathan P, et al. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. Eur J Cancer. 2016;69:226–35. 10.1016/j.ejca.2016.08.004

54. Hutson TE, Michaelson MD, Kuzel TM, Agarwal N, Molina AM, Hsieh JJ, et al. A single-arm, multicenter, phase 2 study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2021;80(2):162–70. 10.1016/j.eururo.2021.03.015

55. McDermott DF, Lee JL, Ziobro M, Suarez C, Langiewicz P, Matveev VB, et al. Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma. J Clin Oncol. 2021;39(9):1029–39. 10.1200/JCO.20.02363

56. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23(1):313–26.e5.

57. Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, Linehan WM, et al. Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol. 2002;26(12):1542–52. 10.1097/00000478-200212000-00002

58. Dodding MP. Folliculin—A tumor suppressor at the intersection of metabolic signaling and membrane traffic. Small GTPases. 2017;8(2):100–5. 10.1080/21541248.2016.1204808

59. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012;62(6):1013–9. 10.1016/j.eururo.2012.06.043

60. Huo L, Sugimura J, Tretiakova MS, Patton KT, Gupta R, Popov B, et al. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum Pathol. 2005;36(3):262–8. 10.1016/j.humpath.2005.01.011

61. Agaimy A, Hartmann A. SMARCB1(INI1)-deficient renal cell carcinoma: Medullary and beyond: Evolving concepts. Pathologe. 2021;42(6):571–7. 10.1007/s00292-021-00985-y

62. Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, et al. Comprehensive molecular characterization identifies distinct genomic and immune hallmarks of renal medullary carcinoma. Cancer Cell. 2020;37(5):720–34.e13. 10.1016/j.ccell.2020.04.002

63. Milowsky MI, Rosmarin A, Tickoo SK, Papanicolaou N, Nanus DM. Active chemotherapy for collecting duct carcinoma of the kidney: A case report and review of the literature. Cancer. 2002;94(1):111–6. 10.1002/cncr.10204

64. Strouse JJ, Spevak M, Mack AK, Arceci RJ, Small D, Loeb DM. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer. 2005;44(4):407–11. 10.1002/pbc.20292

65. Rizzo M, Chiellino S, Gernone A, Porta C. Cisplatin-based chemotherapy for the treatment of metastatic collecting duct carcinomas: A real-world, retrospective analysis. Front Oncol. 2022;12:939953. 10.3389/fonc.2022.939953

66. Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, et al. Updated recommendations on the diagnosis, management, and clinical trial eligibility criteria for patients with renal medullary carcinoma. Clin Genitourin Cancer. 2019;17(1):1–6. 10.1016/j.clgc.2018.09.005

67. Walsh A, Kelly DR, Vaid YN, Hilliard LM, Friedman GK. Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma. Pediatr Blood Cancer. 2010;55(6):1217–20. 10.1002/pbc.22611

68. Hakimi AA, Koi PT, Milhoua PM, Blitman NM, Li M, Hugec V, et al. Renal medullary carcinoma: The Bronx experience. Urology. 2007;70(5):878–82. 10.1016/j.urology.2007.06.1124

69. Maroja Silvino MC, Venchiarutti Moniz CM, Munhoz Piotto GH, Siqueira S, Galapo Kann A, Dzik C. Renal medullary carcinoma response to chemotherapy: A referral center experience in Brazil. Rare Tumors. 2013;5(3):e44. 10.4081/rt.2013.e44

70. Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, et al. Management and outcomes of patients with renal medullary carcinoma: A multicentre collaborative study. BJU Int. 2017;120(6):782–92. 10.1111/bju.13705

71. Wilson NR, Wiele AJ, Surasi DS, Rao P, Sircar K, Tamboli P, et al. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer. 2021;19(6):e401–8. 10.1016/j.clgc.2021.08.007

72. Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, et al. Efficacy and safety of bevacizumab plus erlotinib in patients with renal medullary carcinoma. Cancers (Basel). 2021;13(9):1270. 10.3390/cancers13092170

73. Gollob JA, Upton MP, DeWolf WC, Atkins MB. Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery. Urology. 2001;58(6):1058. 10.1016/S0090-4295(01)01411-X

74. Peyromaure M, Thiounn N, Scotté F, Vieillefond A, Debré B, Oudard S. Collecting duct carcinoma of the kidney: A clinicopathological study of 9 cases. J Urol. 2003;170(4, Pt 1):1138–40. 10.1097/01.ju.0000086616.40603.ad

75. Oudard S, Banu E, Vieillefond A, Fournier L, Priou F, Medioni J, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: Results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Génitales) study. J Urol. 2007;177(5):1698–702. 10.1016/j.juro.2007.01.063

76. Suarez C, Marmolejo D, Valdivia A, Morales-Barrera R, Gonzalez M, Mateo J, et al. Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease. Front Oncol. 2022;12:970199. 10.3389/fonc.2022.970199

77. Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706–20. 10.1093/annonc/mdz056

78. Procopio G, Sepe P, Claps M, Buti S, Colecchia M, Giannatempo P, et al. Cabozantinib as first-line treatment in patients with metastatic collecting duct renal cell carcinoma: Results of the BONSAI trial for the Italian network for research in urologic-oncology (Meet-URO 2 Study). JAMA Oncol. 2022;8(6):910–3. 10.1001/jamaoncol.2022.0238

79. Cajaiba MM, Dyer LM, Geller JI, Jennings LJ, George D, Kirschmann D, et al. The classification of pediatric and young adult renal cell carcinomas registered on the children’s oncology group (COG) protocol AREN03B2 after focused genetic testing. Cancer. 2018;124(16):3381–9. 10.1002/cncr.31578

80. Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature. 2011;480(7375):94–8. 10.1038/nature10539

81. Malouf GG, Camparo P, Oudard S, Schleiermacher G, Theodore C, Rustine A, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): A report from the Juvenile RCC network. Ann Oncol. 2010;21(9):1834–8. 10.1093/annonc/mdq029

82. Caliò A, Brunelli M, Segala D, Pedron S, Remo A, Ammendola S, et al. Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: Investigating prognostic markers and therapy targets. Pathology. 2020;52(3):297–309. 10.1016/j.pathol.2019.11.006

83. Thouvenin J, Alhalabi O, Carlo M, Carril-Ajuria L, Hirsch L, Martinez-Chanza N, et al. Efficacy of cabozantinib in metastatic MiT family translocation renal cell carcinomas. Oncologist. 2022;27(1):1041–1047. 10.1093/oncolo/oyac158

84. Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, et al. Cabozantinib in advanced non-clear cell renal cell carcinoma: A multicentre, retrospective, cohort study. Lancet Oncol. 2019;20(4):581–90. 10.1016/S1470-2045(18)30907-0

85. Goethe U. Randomized phase-II study of nivolumab plus ipilimumab vs. standard of care in untreated and advanced non-clear cell RCC. [Internet]. [cited July 10, 2023]. Available from: https://ClinicalTrials.gov/show/NCT03075423

86. Michael B. Atkins MD, Bristol-Myers S, Hoosier Cancer Research N. Study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma. [Interent]. [cited July 10, 2023]. Available from: https://ClinicalTrials.gov/show/NCT03117309

87. Washington University School of M, Merck S, Dohme LLC. Lenvatinib (LEN) in combination with pembrolizumab (KEYtruda) in subjects with locally advanced or metastatic non-clear cell renal cell carcinoma (the LENKYN trial) [Internet]. [cited July 10, 2023]. Available from: https://ClinicalTrials.gov/show/NCT04267120

88. Stellato M, Buti S, Maruzzo M, Bersanelli M, Ermacora P, Maiorano BA, Prati V,, et al. Clinical outcome of patients with metastatic papillary and chromophobe renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a). Ann Oncol. 2022;33(Suppl_7):S660–S680. 10.1016/j.annonc.2022.07.1565

89. Ontario Clinical Oncology G, Bristol-Myers S. SBRT with combination ipilimumab/nivolumab for metastatic kidney cancer [Internet]. [cited December 31, 2022]. Available from: https://ClinicalTrials.gov/show/NCT04090710

90. Bradley AM, Bristol-Myers S, Exelixis, Dana-Farber Cancer I. Cabozantinib in combo with NIVO + IPI in advanced NCCRCC [Internet]. [cited July 10, 2023]. Available from: https://ClinicalTrials.gov/show/NCT04413123

91. National Cancer I. Testing the effectiveness of two immunotherapy drugs (nivolumab and ipilimumab) with one anti-cancer targeted drug (cabozantinib) for rare genitourinary tumors [Internet]. [cited February 28, 2023]. Available from: https://ClinicalTrials.gov/show/NCT03866382

92. Pook D. Australian, New Zealand U, Prostate Cancer Trials G. ANZUP – Non-clear cell post immunotherapy CABozantinib (UNICAB) [Internet]. [cited October 30, 2022]. Available from: https://ClinicalTrials.gov/show/NCT03685448.

93. Guo H. Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma [Internet]. [cited July 10, 2023]. Available from: https://ClinicalTrials.gov/show/NCT04535687

94. Queen Mary University of L, Vall d’Hebron Institute of O, AstraZeneca. MEDI4736 Combinations in metastatic renal cell carcinoma [Internet]. [cited March 2023]. Available from: https://ClinicalTrials.gov/show/NCT02819596.

95. Rasmussen IM. Individualized treatment strategy for patients with metastatic non-clear cell renal cell carcinoma [Internet]. [cited September 6, 2022]. Available from: https://ClinicalTrials.gov/show/NCT04644432.

96. Maughan BL. Start of a new era: Management of non-clear cell renal cell carcinoma in 2022. Curr Oncol Rep. 2022;24(9):1201–8. 10.1007/s11912-022-01269-1

97. Bakouny Z, Vokes N, Gao X, Nassar A, Alaiwi SA, Flippot R, et al. Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2019;37(15_suppl):4514. 10.1200/JCO.2019.37.15_suppl.4514

98. Iacovelli R, Ciccarese C, Bria E, Bracarda S, Porta C, Procopio G, et al. Patients with sarcomatoid renal cell carcinoma–Re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. Eur J Cancer. 2020;136:195–203. 10.1016/j.ejca.2020.06.008

99. Ciccarese C, Alfieri S, Santoni M, Santini D, Brunelli M, Bergamini C, et al. New toxicity profile for novel immunotherapy agents: Focus on immune-checkpoint inhibitors. Expert Opin Drug Metab Toxicol. 2016;12(1):57–75. 10.1517/17425255.2016.1120287

100. Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008–19. 10.1001/jamaoncol.2019.0393

101. Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune-related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis. BMC Med. 2015;13:211. 10.1186/s12916-015-0455-8

102. Silagy AW, Flynn J, Mano R, Blum KA, Marcon J, DiNatale RG, et al. Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. Urol Oncol. 2019;37(11):811.e9–16. 10.1016/j.urolonc.2019.07.011

103. Marchioni M, Bandini M, Preisser F, Tian Z, Kapoor A, Cindolo L, et al. Survival after cytoreductive nephrectomy in metastatic non-clear cell renal cell carcinoma patients: A population-based study. Eur Urol Focus. 2019;5(3):488–96. 10.1016/j.euf.2017.11.012

104. Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Mistretta FA, et al. Association between systemic therapy and/or cytoreductive nephrectomy and survival in contemporary metastatic non-clear cell renal cell carcinoma patients. Eur Urol Focus. 2021;7(3):598–607. 10.1016/j.euf.2020.04.009

105. Ciccarese C, Brunelli M, Montironi R, Fiorentino M, Iacovelli R, Heng D, et al. The prospect of precision therapy for renal cell carcinoma. Cancer Treat Rev. 2016;49:37–44. 10.1016/j.ctrv.2016.07.003

106. Bratslavsky G, Mendhiratta N, Daneshvar M, Brugarolas J, Ball MW, Metwalli A, et al. Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. Cancer. 2021;127(21):3957–66. 10.1002/cncr.33679

107. Shuch B, Singer EA, Bratslavsky G. The surgical approach to multifocal renal cancers: Hereditary syndromes, ipsilateral multifocality, and bilateral tumors. Urol Clin North Am. 2012;39(2):133–48, v. 10.1016/j.ucl.2012.01.006

108. Santoni M, Buti S, Conti A, Porta C, Procopio G, Sternberg CN, et al. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Target Oncol. 2015;10(4):517–22. 10.1007/s11523-014-0356-3

109. Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI, et al. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res. 2002;8(10):3226–31.